Karyopharm Therapeutics
KPTI
87 hedge funds and large institutions have $41.2M invested in Karyopharm Therapeutics in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 23 reducing their positions, and 18 closing their positions.
317% more call options, than puts
Call options by funds: $196K | Put options by funds: $47K
0.04% more ownership
Funds ownership: 3.18% → 3.22% (+0.04%)
9% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 23
4% less funds holding
Funds holding: 91 → 87 (-4)
16% less capital invested
Capital invested by funds: $49.2M → $41.2M (-$8.02M)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.73M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.61M |
| 3 |
Jane Street
New York
|
+$438K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$291K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$257K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$2.79M |
| 2 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$934K |
| 3 |
JP Morgan Chase
New York
|
-$894K |
| 4 |
D.E. Shaw & Co
New York
|
-$659K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$539K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FCMT
101
Founders Capital Management (Texas)
Houston,
Texas
| – | -$1.66K | -133 | Closed |
|
|
GSEP
102
Golden State Equity Partners
South Coast Metro,
California
| – | -$1.49K | -120 | Closed |
|
103
Lazard Asset Management
New York
| – | -$1K | -105 | Closed |
|
|
AAP
104
Arax Advisory Partners
Denver,
Colorado
| – | -$447 | -36 | Closed |
|
|
AF
105
Advisornet Financial
Minnetonka,
Minnesota
| – | -$166 | -13 | Closed |
|
KPTI Hedge Fund Activity: Q4 2024 in Review
87 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q4 2024, worth a combined $41.2M — down 16% from $49.2M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of KPTI and 14 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 21 added.
The largest buyer was Morgan Stanley, adding an estimated $2.73M. The largest seller was Eversept Partners, cutting an estimated $2.79M.
- 87 institutional investors held Karyopharm Therapeutics (KPTI) as of Q4 2024, down from 91 in Q3 2024.
- Funds reported $41.2M of Karyopharm Therapeutics stock for Q4 2024, down 16% quarter-over-quarter.
- 14 funds opened new Karyopharm Therapeutics positions in Q4 2024 and 18 closed out, a net change of -4 holders.
- The largest Karyopharm Therapeutics buyer in Q4 2024 was Morgan Stanley, an estimated $2.73M added.
- The largest Karyopharm Therapeutics seller in Q4 2024 was Eversept Partners, an estimated $2.79M sold.
Based on aggregated 13F filings for Q4 2024.